Evidence map›Paper›PMID 33969279›Full record

ArticleACS applied nano materials2021

Carbon Quantum Dots for Treatment of Amyloid Disorders.

Erick Damian Guerrero, Angela Marlene Lopez-Velazquez, Jyoti Ahlawat, Mahesh Narayan

Open access · greenAbstract read
In one paragraph

Article in ACS applied nano materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 62 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Carbon quantum dots in bioimaging and biomedicines.Frontiers in bioengineering and biotechnology · 2023
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Erick Damian GuerreroDepartment of Chemistry and Biochemistry, The University of Texas at El Paso (UTEP), El Paso, Texas 79968, United States.ORCID 0000-0002-2076-3537
Angela Marlene Lopez-VelazquezDepartment of Biological Sciences, Bioscience Research Building, Border Biomedical Research Center, the Cellular Characterization and Biorepository Core Facility, The University of Texas at El Paso (UTEP), El Paso, Texas 79968, United States.
Jyoti AhlawatDepartment of Chemistry and Biochemistry, The University of Texas at El Paso (UTEP), El Paso, Texas 79968, United States.ORCID 0000-0002-2361-334X
Mahesh NarayanDepartment of Chemistry and Biochemistry, The University of Texas at El Paso (UTEP), El Paso, Texas 79968, United States.ORCID 0000-0002-2194-5228
The University of Texas at El Paso · US

Funding

UTEP Border Biomedical Research CenterU54MD007592 · NIMHD · UNIVERSITY OF TEXAS EL PASO · PI Gabriel Andrew Frietze · 2019 to 2026
$35.1M
TOXICOLOGY PROJECTG12RR008124 · NCRR · UNIVERSITY OF TEXAS EL PASO · PI AGUILERA, RENATO J · 1992 to 2011
$20.8M
TCCG12MD007592 · NIMHD · UNIVERSITY OF TEXAS EL PASO · PI KIRKEN, ROBERT A. · 2012 to 2018
$19.4M
Phase II of BUILDing SCHOLARSUL1GM118970 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI ALEY, STEPHEN B, BOLAND, THOMAS · 2015 to 2023
$17.9M
RISE Scholars Program at UTEPR25GM069621 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI AGUILERA, RENATO J · 2004 to 2021
$11.2M
Summer Mentoring And Research Training: Methods In Neuroscience of Drug-abuse (SMART-MIND)R25DA033613 · NIDA · UNIVERSITY OF TEXAS EL PASO · PI Karina C Canaba, LAURA ELENA ODELL · 2012 to 2026
$1.5M
Understanding PDI-related neurotoxicity and advancing preventative approachesSC3GM111200 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI NARAYAN, MAHESH · 2016 to 2019
$453k
NCRR NIH HHS G12 RR008124NIDA NIH HHS R25 DA033613NIGMS NIH HHS R25 GM069621NIGMS NIH HHS SC3 GM111200NIGMS NIH HHS UL1 GM118970NIMHD NIH HHS G12 MD007592NIMHD NIH HHS U54 MD007592
6 · The paper itself

Abstract

Prion-like amyloids self-template and form toxic oligomers, protofibrils, and fibrils from their soluble monomers; a phenomenon that has been implicated in the onset and progress of neurodegenerative disorders such as Alzheimer's (AD), Parkinson's (PD), Huntington's, and systemic lysozyme amyloidosis. Carbon quantum dots (CQDs), sourced from Na-citrate as a carbon precursor were synthesized and characterized before being tested for their ability to intervene in amyloidogenic (fibril-forming) trajectories. Hen-egg white lysozyme (HEWL) served as a model amyloidogenic protein. A pulse-chase lysozyme fibril-forming assay developed to examine the impact of CQDs on the HEWL amyloid-fibril-forming trajectory used ThT fluorescence as a reporter of mature fibril presence. The results revealed that the Na-citrate-derived CQDs were able to intervene at multiple points along the fibril-forming trajectory by preventing the conversion of both monomeric and oligomeric HEWL intermediates into mature fibrils. In addition, and importantly, the carbon nano material (CNM) was able to dissolve oligomeric HEWL into monomeric HEWL and provoke the disaggregation of mature HEWL fibrils. These results suggest that Na-citrate CQD's intervene in amyloidogenesis by multiple mechanisms. The gathered data, coupled with cell-line results demonstrating the relatively low cytotoxicity of Na-citrate CQDs, suggest that this emerging CNM has the potential to intervene both prophylactically and therapeutically in protein misfolding diseases. The aforementioned findings are likely to enable Na-citrate CQDs to eventually transition to both cell-line and preclinical models of protein-misfolding-related disorders. Importantly, the study outcomes positions Na-citrate CQDs as an important class of chemical, nanotechnological, and biobased interventional tools in neuroscience.

Indexed as

amyloid fibrilscarbon nano materialscarbon quantum dotshen-egg white lysozymeprophylacticsprotein misfoldingtherapeutics

Identifiers

PMID33969279
PMCPMC8101282
OpenAlexW3134683971

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.